To identify a robust therapeutic, we chose a diverse array of NSCLC lines (ATCC): H460 has overexpression of TP53 mRNA, A549 has mutated KRAS, and HCC827 has mutated EGFR. Here, KRAS is linked to non-small cell lung carcinoma.